#Israel #Tel Aviv #Galmed Pharmaceuticals #Aramchol #VCU

Galmed Pharmaceuticals Reports Financial Results for Q3 2025

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), a clinical-stage biopharmaceutical firm, has released its third-quarter financial results for 2025, showcasing both financial stability and promising advancements in research. The company, known for its focus on liver, cardiometabolic, and gastrointestinal oncology treatments, reported a cash and cash equivalents total of approximately $19.2 million as of September 30, 2025, which represents an increase from $15.4 million recorded at the close of 2024.

Financial Overview

In terms of losses, Galmed recorded a net loss of about $2.0 million, translating to $0.33 per share during the quarter, a slight increase from a net loss of approximately $1.9 million, or $2.31 per share, in the same period the previous year. The company's research and development expenditures rose to around $1.1 million, from $0.7 million year-over-year, primarily due to escalating expenses linked to clinical and pre-clinical studies. In contrast, general and administrative costs decreased to approximately $1.0 million from $1.3 million in Q3 2024, attributed largely to reductions in salaries and benefits. Notably, Galmed’s financial income netted around $0.2 million compared to the previous year’s financial income of $0.1 million.

Recent Developments

Galmed has been at the forefront of research and development in biopharmaceuticals, with significant progress reported in its collaboration with Virginia Commonwealth University (VCU). On November 17, 2025, the company announced top-line results of a study evaluating the efficacy of Aramchol in overcoming drug resistance in gastrointestinal cancers. The findings demonstrated that a combination of Aramchol, Stivarga®, and Metformin notably enhanced the destruction of gastrointestinal tumor cells both in vivo and in vitro.

Furthering its clinical endeavors, on November 18, 2025, Galmed released positive top-line results from its AM-001 study, a Phase 1 bioavailability assessment of Aramchol Meglumine. This progress is indicative of the company's commitment to advancing its research pipeline and enhancing treatment options for patients.

In 2025, Galmed successfully raised approximately $9.3 million through various financing strategies, including equity line and ATM facilities. This influx of resources is expected to provide a solid foundation for future developments.

Company Vision

Galmed Pharmaceuticals is dedicated to enhancing patient outcomes through innovative treatments for liver diseases and expanding its pipeline to address cardiometabolic and oncological indications. With a focus on the development of Aramchol, the company aims to diversify its offerings in alignment with its expertise in drug development.

In conclusion, Galmed’s third-quarter update underscores its financial growth and pivotal research advancements. As it navigates the complexities of drug development and regulatory landscapes, the company remains poised to make impactful contributions to biopharmaceutical advancements, targeting unmet medical needs across various health areas.

With relevant financial data and promising clinical trials, Galmed Pharmaceuticals is on track to enhance its influence in the biopharmaceutical industry, demonstrating resilience and innovation amidst the constantly evolving healthcare landscape.